ArticleInfection2026
Molecular epidemiology of community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA): sequence types, virulence profiles, and antimicrobial resistance in a Belgian hospital network.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study characterizes 109 MRSA isolates collected at a major hospital network in Antwerp, Belgium, focusing on their classification as community-acquired (CA-MRSA) or hospital-acquired (HA-MRSA), antimicrobial susceptibility profiles, genotypic resistance determinants, virulence factors, and sequence type (ST) distribution.
methodsThis study was conducted retrospectively. MRSA isolates were collected from patients presenting to facilities within the "Ziekenhuis aan de Stroom (ZAS)" hospital network. The strains were prepared for whole genome sequencing with the Nextera XT sample preparation kit (Illumina), followed by sequencing on the Illumina MiSeq platform.
resultsOf the 109 sequenced isolates, 83 (76,1%) were classified as CA-MRSA and 26 (23,9%) as HA-MRSA. Seventy-three (67,0%) isolates originated from clinical samples and 36 (33,0%) from screening samples. MLST revealed substantial genetic diversity. CA-MRSA clinical isolates were most frequently associated with ST5, ST6, ST152, and ST30, whereas HA-MRSA clinical isolates were dominated by ST8. Panton-Valentine leukocidin (PVL) genes were identified in 29 of the 109 isolates (26,6%). Antimicrobial susceptibility differed between CA-MRSA and HA-MRSA and was influenced by sequence type.
conclusionIn this study, the majority of isolates were classified as CA-MRSA based on a pragmatic epidemiological classification. Multiple sequence types (STs) are involved and different STs appear to be associated with varying degrees of clinical severity and virulence genes. Antimicrobial susceptibility profiles are influenced by the circulating ST, which may in turn affect empirical treatment strategies. These findings underscore the need for nationwide surveillance systems for CA-MRSA.
Indexed as
Identifiers
42430113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.